BioNTech, which co-developed its Covid-19 vaccine with Pfizer, said on Monday that its shots do not require any new adaptations to protect against new emerging variants of the coronavirus, echoing two recently concluded studies showing that the mRNA shot offered robust protection against the more infectious variants that first emerged in the U.K. and Brazil.
Stay Connected
Forbes on Facebook: [ Ссылка ]
Forbes Video on Twitter: [ Ссылка ]
Forbes Video on Instagram: [ Ссылка ]
More From Forbes: [ Ссылка ]
